EXTON, Pa., Dec. 31 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 27th Annual J.P. Morgan Healthcare Conference at 5:30 P.M. ET (2:30 P.M. PT) on Wednesday, January 14, 2009. The conference is being held at the Westin St. Francis Hotel in San Francisco.
ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.
ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.
CONTACT: William C. Roberts, Vice President, Corporate Communications,
+1-610-321-6288, or Robert A. Doody Jr., Manager, Corporate Communications,
+1-610-321-6290, both of ViroPharma Incorporated
Web site: http://www.viropharma.com//
